We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor.  Starting from a High Throughput Screening (HTS) hit, medicinal chemistry efforts were geared towards the optimization of FAAH inhibition in vitro potency, improvement of the pharmacokinetic (PK) profile, and achievement of efficacy in rodent inflammatory and neuropathic pain in vivo assays.

Discovery of MK-4409, a novel oxazole FAAH inhibitor for the treatment of inflammatory and neuropathic pain

248th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.